Ami Organics Ltd IPO

Closed

IPO Details

  • Open Date 01-Sep-21
  • Close Date 03-Sep-21
  • Lot Size 24
  • IPO Size ₹ 565.39 - 571.96 Cr Cr
  • IPO Price Range ₹ 603 - 610
  • Min Investment ₹ 14,472
  • Listing Exchange NSE, BSE
  • Basis of Allotment 08-Sep-21
  • Refunds 09-Sep-21
  • Credit to Demat Account 13-Sep-21
  • Listing Date 14-Sep-21

Ami Organics Ltd IPO Subscription Status

Ami Organics IPO Subscription Status

 

Category Subscription Status
Qualified Institutional (QIB) 86.64 Times
Non-Institutional (NII) 154.81 Times
Retail Individual 13.36 Times
Total 64.54 Times

 

Ami Organics IPO Subscription Details (Day by Day)

 

Date QIB NII Retail Total
September 01, 2021 17:00 1.39x 0.40x 2.82x 1.90x
September 02, 2021 17:00 1.43x 1.51x 6.32x 3.90x
September 03, 2021 17:00 86.64x 154.81x 13.36x 64.54x

IPO Synopsis

The offer comprises a fresh issue and an offer for sale. The fresh issue is of ₹200cr after the company chose the pre-IPO placement of ₹100 cr. Out of the proceeds from the IPO and pre-IPO placement, ₹140 cr would be utilized towards repayment/prepayment of certain loans availed by the company while ₹90cr would be used for funding the working capital requirements of the company and the balance of the fresh issue would be used for general corporate purposes. The offer for sale is 6,059,600 shares amounting to ₹369.6cr, the proceeds of which would go directly to the selling shareholders.

Ami Organics Shareholding

% Shareholding

Pre- IPO(%)

Post-IPO(%)

Promoter & Promoter Group

47.22

41.00

Public

52.78

59.00

Source: RHP

About Ami Organics Ltd

Ami Organics Limited is a research and development (‘R&D’) driven manufacturer of specialty chemicals with varied end usage, focusing on the development and manufacturing of advanced pharmaceutical intermediates (‘Pharma Intermediates’) for regulated and generic active pharmaceutical ingredients (‘APIs’) and New Chemical Entities (‘NCE’) and key starting material for agrochemical and fine chemicals, especially from their recent acquisition of the business of Gujarat Organics Limited (‘GOL’). The Pharma Intermediates which we manufacture, find application in certain high-growth therapeutic areas including anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant and anti-coagulant, commanding significant market share both in India and globally.

Ami Organics - Financials

 

(`₹ in crore)

FY19

FY20

FY21

Revenue from Operations

238.5

239.6

340.6

EBITDA

42.0

41.0

80.1

EBITDA Margin (%)

17.64%

17.12%

23.53%

PAT

23.2

27.4

53.9

PAT Margin (%)

9.77%

11.46%

15.85%

Source: RHP


Competitive Strengths:

Some of the competitive strengths are as follows

1.  Diversified product portfolio ably supported by strong R&D and process chemistry skills.
Based on the existing business strategy of early identification of molecules for development and supply, Ami Organics has developed and commercialised over 450 Pharma Intermediates for APIs including Dolutegravir, Trazodone, Entacapone, Nintedanib and Rivaroxaban and NCEs across 17 high growth therapeutic areas since inception, such as anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant and anti-coagulant. As a result of their R&D capabilities, the company has been able to file eight process innovation patent applications in India applications (in respect of intermediates used in the manufacture of Apixaban, Rivaroxaban, Nintedanib, Vortioxetine, Selexipag, Pimavanserin, Efinaconazole and Eliglustat).

2. Extensive geographical presence and diversified customer base with long standing relationships
Ami Organics caters to domestic and certain multi-national pharmaceutical companies which cater to the large and fast-growing markets of Europe, China, Japan, Israel, UK, Latin America and the USA. In FY21 the company’s revenue from exports contributed 51.57% of the total revenue from operations. The company supplies their products to 25 countries and has long-standing relationships with     numerous domestic and global pharmaceutical companies. Diversification of their customer base across the domestic and global markets has limited the company’s exposure to a risk of concentration, enabling them to further diversify and expand their business relationships. Thirteen of Ami Organic’s customers have been their customers since the past 10 years and fifty of their customers have been customers since the past five years.

3. High entry barriers in the chemicals manufacturing industry
The pharmaceutical intermediates business has high entry barriers inter alia due to: (a) a long gestation period to be enlisted as a supplier with the customers, particularly with the customers in US and European countries, which requires suppliers to adhere to strict compliance requirements, leading to a high regulatory gestation period; and (b) the involvement of complex chemistries in the manufacturing process, which is difficult to commercialize on a large scale. APIs and NCEs manufactured by Ami Organic’s customers, where their products are used, and where such use has been formally recognised in filings with regulatory agencies, any change in the vendor of the product may require significant time and cost for the customer resulting in a propensity amongst customers to continue with the same set of suppliers. This highlights the high entry barriers in the industry in which they operate.

Risk Factors:
Some of the risk factors are as follows

1.    The continuing impact of the COVID-19 pandemic on their business and operations is uncertain and it may be significant and continue to have an adverse effect on their business.
2.    The company is subjected to strict quality requirements, regular inspections and audits, and any failure or quality control problems can damage their reputation and have an adverse effect on their business.
3.    Non-compliance with and adverse changes in health, safety, labour, and environmental laws and other similar regulations applicable to their manufacturing operations may adversely affect their business.

 

Ami Organics 5paisa Review

Considering the future growth potential of the specialty chemical industry, plans for strategic acquisition and expansions, diversified products and customer base, and strong technical capabilities of the company, we recommend ‘Subscribe’ to the issue with a long-term perspective.

How to apply for IPO?

  • Login to your 5paisa account and select the issue in the current IPO section

  • Enter the number of lots and price at which you wish to apply for

  • Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange

  • You will receive a mandate notification to block funds in your UPI app

  • Approve the mandate request on your UPI and funds will be blocked

Contact Details of Ami Organics Ltd IPO

Contact Information

Ami Organics Limited
Plot No. 440/4, 5 & 6, Road No. 82/A
GIDC Sachin, Surat – 394 230


Phone: +91 261 239 7193
Email: cs@amiorganics.com
Website: http://www.amiorganics.com/

Ami Organics Ltd IPO Register

Link Intime India Private Ltd
 Link Intime India Private Ltd
 C 101, 247 Park, L.B.S.Marg,
 Vikhroli (West), Mumbai - 400083

Phone: +91-22-4918 6270
Email: amiorganics.ipo@linkintime.co.in
Website: http://www.linkintime.co.in

Ami Organics Ltd IPO Lead Manager

  • Ambit Private Limited
  • Axis Capital Limited
  • Intensive Fiscal Services Private Limited

IPO NewsIPO News

Top Stories for you
Story Blog
Trust Fintech IPO Subscribed 108.63 times

Trust Fintech IPO is book-built issue of ₹63.45 crores, consisting entirely of fresh issue shares totalling 62.82 lakh. Trust Fintech IPO commenced its subscription period on March 26, 2024, & concludes today, March 28, 2024. Allotment is scheduled for Tuesday, April 2, 2024, with listing on NSE SME tentatively set for Thursday, April 4, 2024.

Most Popular
Story Blog
Aspire & Innovative IPO Subscribed 15.17 times
Blue Pebble IPO Subscribed 56.32 times
SRM Contractors IPO Subscribed 86.56 times

IPO BlogIPO Blog

Top Stories for you
Naman In-Store (India) IPO Allotment Status

Building blocks of the Naman In-Store (India) Ltd IPO Naman In-Store (India) IPO is book built issue of Rs 25.35 crores. It consists entirely of fresh issue of 28.48 lakh shares. Naman In-Store (India) IPO opens for subscription on March 22, 2024, & closes on March 27, 2024. allotment is expected to be finalized on March 28, 2024. Naman In-Store (India) IPO will list on NSE SME with tentative listing date set ...

IPO GuideIPO Guide

Top Stories for you
IPO Cycle

The IPO cycle, also referred to as Initial Public Offering Cycle, allows private companies to go public and offer the company's shares to the general public for the first time. It ...

 
Greenshoe Option
How To Cancel An IPO Application
NFO vs IPO
What Is FPO In Share Market?
What is an Abridged Prospectus?
How to Buy IPO Online in India